NPPA: For 74 medications, including those for diabetes and high blood pressure, the Indian government’s National Pharmaceutical Pricing Authority (NPPA) has established retail prices. According to the decision made at the 109th meeting of the Authority held on February 21, the pricing has been established in accordance with the Drugs (Prices Control) Order 2013. According to the NPPA’s notification, the cost of one extended-release tablet of dapagliflozin sitagliptin and metformin hydrochloride has been set at 27.75 rupees.
Specific price adjustments for various medications
Furthermore, the cost of blood pressure medicines like telmisartan and bisoprolol fumarate has been lowered to 10.92 per tablet. In addition, the NPPA revised the ceiling prices for 80 medications (NLEM 2022), including those used to treat neutropenia and epilepsy. The cost of one vial of Filgrastim injection has been set at $1,034.51 and the price of sodium valproate (20 mg) tablets has decreased to $3.20 per tablet. The cost of the steroid hydrocortisone has been reduced to 13.28 per tablet.
Must Read: China’s High-Altitude Spy Balloons – A Threat to National Security and Global Stability?
NPPA’s responsibility for regulating drug prices in India
The NPPA is in charge of establishing/revising prices for formulations and controlled bulk drugs as well as enforcing drug costs and availability in the nation. The regulatory body also keeps an eye on decontrolled drug prices to make sure they remain within acceptable ranges. The Drugs (Prices Control) Order’s provisions are enforced by the NPPA, which is also in charge of recouping consumer overpayments for controlled drug purchases from manufacturers.
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK, INSTAGRAM, and TWITTER.
